Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-54

comments about the two additional indications that show great promise


Everything Starpharma is 'promising' according to JF & Co. over the last couple of decades and yet here we sit in 2023 with a MC of circa $50 million and not one single DEP® drug license deal after all the DEP® clinical trials (research agreements with no payments to Starpharma aren't license deals) and of course the poor SPL7013 revenues reflected in the financial reporting year after year .... perhaps there's your answer ?


I would also add that the word promising was used 8 times in yesterdays announcement alone ... not to mention how many times it was used in the recent Annual Report etc .... perhaps it's lost its affect with anything Starpharma publishes now through over use ?